Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
- PMID: 37533200
- PMCID: PMC10404523
- DOI: 10.4093/dmj.2023.0188
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Comment on
-
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.Diabetes Metab J. 2023 May;47(3):394-404. doi: 10.4093/dmj.2022.0221. Epub 2023 Mar 6. Diabetes Metab J. 2023. PMID: 36872060 Free PMC article.
-
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404).Diabetes Metab J. 2023 Jul;47(4):571-572. doi: 10.4093/dmj.2023.0164. Epub 2023 Jul 27. Diabetes Metab J. 2023. PMID: 37533199 Free PMC article. No abstract available.
References
-
- VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the e-value. Ann Intern Med. 2017;167:268–74. - PubMed
-
- Centers for Disease Control and Prevention, Department of Health and Human Services . Atlanta: CDC; 2020. National Diabetes Statistics Report 2020.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
